Indian based Pharma major Ranbaxy Laboratories Limited on Monday stated it had obtained the acceptance of the Central Drugs Standard Control Organisation (CDSCO) to produce and market Synriam™ for the therapy of uncomplicated malaria in adults induced by the Plasmodium vivax parasite.
Phase III clinical studies of the medicine effectively confirmed the efficacy and tolerability of Synriam™ as equivalent to chloroquine.
Last year, Ranbaxy introduced Synriam™ for the therapy of uncomplicated Plasmodium falciparum malaria in the nation. Since its launch, the drug has efficiently handled around 10 lakh sufferers. The organization has also obtained approval to perform Phase III clinical studies of the paediatric formulation of the medicine.
CEO & MD of Ranbaxy Arun Sawhney stated, “Synriam™ is a new-age cure for malaria and is quick emerging as the recommended choice in the hands of physicians. This acceptance makes it one of the few treatments in the world that efficiently treats both Plasmodium vivax and Plasmodium falciparum malaria. Ranbaxy continues to be committed in its battle towards malaria and we are making all attempts to make this novel treatment available to sufferers around the globe.”
Synriam™ offers quick relief from most malaria-related symptoms, which includes fever, and has a great cure rate of above 95%. It conforms to the suggestions of the WHO for using combination treatment in malaria.